← Back to catalogue
Research draft

phaeochromocytoma

vr.tr.phaeochromocytoma · XCT.STA

Let an agent explain phaeochromocytoma and paraganglioma, relay symptoms, genetics, diagnosis and general treatment from endocrinology sources, describe the tumour sites the registry aliases name, and distinguish these tumours from other adrenal tumours, from anxiety or panic and from essential hypertension, routing crises to emergency care.

Thing Registry Cross-cutting context

Research draft, second pass

A second pass drafted this model: the structure a model of this thing needs, and what is known about it in the world. The line under this one says how the second half was obtained - researched against sources, or recalled without web access, in which case nothing here was read anywhere and every claim is a lead to verify. Unreviewed either way.

written by Claude from model knowledge without web access - no source was read, every claim is a lead to verify

Researched by: Claude

Purpose and description

Let an agent explain phaeochromocytoma and paraganglioma, relay symptoms, genetics, diagnosis and general treatment from endocrinology sources, describe the tumour sites the registry aliases name, and distinguish these tumours from other adrenal tumours, from anxiety or panic and from essential hypertension, routing crises to emergency care.

A rare neuroendocrine tumour of the adrenal medulla that produces catecholamines such as adrenaline and noradrenaline, causing episodes of high blood pressure, headache, sweating and palpitations, closely related to paragangliomas, which arise from extra-adrenal paraganglia in the abdomen, retroperitoneum or head and neck, such as the glomus jugulare tumour; many cases are hereditary, and although often classed as benign, all such tumours are now considered to have metastatic potential. A hypertensive crisis needs emergency care. The model routes people to clinicians.

What it is for: Not applicable; a tumour.

It can be route crises first; explain tumour and symptoms; relay diagnosis and treatment; distinguish related conditions.

Distinguishing features

Catecholamine excess

Episodic symptoms

Strong genetic link

Adrenal or extra-adrenal

What it looks like

Not a visible object; an adrenal or paraganglion mass.

Physical character

incidence: about 2-8 per million per year - estimates

hereditary share: about 30-40 percent

classic triad: headache, sweating, palpitations list

WHO 2017: all considered potentially metastatic note

How it is recognised

Catecholamine-producing neuroendocrine tumour

Adrenal phaeochromocytoma, paraganglioma, extra-adrenal retroperitoneal paraganglioma, glomus jugulare tumour

Adrenal adenomas are usually non-functioning; panic attacks lack a tumour; essential hypertension has no single cause

Related models

is a kind of - in registry terms

neuroendocrine tumor

arises from -

adrenal medulla

is related to -

paraganglioma

produces - and epinephrine

norepinephrine

In practice

Families and kinds

adrenal phaeochromocytoma

sympathetic abdominal paragangliomas

head and neck paragangliomas such as glomus jugulare

hereditary syndromes such as MEN2, VHL and SDH-related

metastatic disease

Identifiers

ICD-10 D35.0 benign neoplasm of adrenal gland

MeSH D010673 Pheochromocytoma

Standards and regulation

Endocrine Society clinical practice guidelines

Genetic testing recommendations

Failure modes and hazards

Hypertensive crisis

Agents giving personal medical advice

Registry parent benign neoplasm understating metastatic potential

Also called

adrenal gland pheochromocytomasporadic pheochromocytoma/secreting paragangliomaparagangliomaextra-adrenal retroperitoneal paragangliomaextra-adrenal paragangliomaglomus jugulare tumorGangliocytic paragangliomaAbdominal chemodectomas with cutaneous angiolipomasparasympathetic paragangliomasympathetic paragangliomaparagangliomas 1

Where this came from

wikidata · CC0 1.0

Drafted structure

Bundle to layer to finding to question, as the second pass will find it: 4 bundles · 8 layers · 8 findings · 16 questions.

Understand What phaeochromocytoma is.

Clinical.

Definition

Definition.

Definition

Definition.

  1. What is phaeochromocytoma, and how does it differ from paraganglioma, other adrenal tumours, panic attacks and essential hypertension? definition
  2. Is someone having a severe headache with very high blood pressure, chest pain or confusion, which needs emergency services? boundary

Sites

Sites.

Sites

Sites.

  1. What are adrenal, retroperitoneal and head and neck paragangliomas such as glomus jugulare? definition
  2. Which entry fits the specific site? action
Biology Biology and genetics.

Science.

Hormones

Catecholamines.

Hormones

Hormones.

  1. How do catecholamines cause the symptoms? provenance
  2. Which references are standard? provenance

Genetics

Genetics.

Genetics

Genetics.

  1. Which hereditary syndromes are involved, and why is genetic testing recommended? provenance
  2. Which sources are cited? provenance
Care Diagnosis and treatment.

Clinical.

Diagnosis

Diagnosis.

Diagnosis

Diagnosis.

  1. How is it diagnosed with metanephrine tests and imaging, in general terms? provenance
  2. Which entry fits metanephrine? action

Treatment

Treatment.

Treatment

Treatment.

  1. What general treatment approaches, including pre-operative preparation and surgery, do guidelines describe? provenance
  2. Which entry fits adrenalectomy? action
Context Classification and support.

Context.

Classification

Classification.

Classification

Classification.

  1. Why did WHO stop classifying these tumours as benign or malignant? provenance
  2. Which entry fits WHO classification of tumours? action

Support

Support.

Support

Support.

  1. What patient organisations support people and families? provenance
  2. Which entry fits rare disease support organisations? action

What the second pass must settle

  • Should paraganglioma be a separate primary entry?
  • How should endocrinology sources be linked?
  • The registry parent endocrine organ benign neoplasm conflicts with the current view of metastatic potential; should it be reviewed?